Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study.
Stanislas PolAlexander J ThompsonMichelle CollinsElisa VenierLaurent CotteMontserrat Laguno CentenoJorge MeraThomas ReibergerMargaret BurroughsDimitri G SemizarovAlexandru M IacobAnne WelhavenLinda M FredrickJoseph S DoylePublished in: Hepatology (Baltimore, Md.) (2024)
Eight-week G/P therapy was effective and well-tolerated in patients with acute HCV infection. Data support further investigation of G/P in acute HCV to shorten care cascades, reduce transmission, and support HCV elimination.
Keyphrases
- hepatitis c virus
- human immunodeficiency virus
- healthcare
- liver failure
- palliative care
- quality improvement
- randomized controlled trial
- drug induced
- big data
- stem cells
- intensive care unit
- machine learning
- bone marrow
- combination therapy
- artificial intelligence
- gestational age
- mesenchymal stem cells
- hiv infected
- cell therapy
- health insurance
- affordable care act
- extracorporeal membrane oxygenation
- preterm birth